Issue 45, 2022

Enzyme activatable photodynamic therapy agents targeting melanoma

Abstract

Cell-selective activity regulation of therapeutics is necessary for efficient personalized treatments with minimal off-target effects. Here, the first example of a structurally simple, pyridinium BODIPY-based, tyrosinase activatable photosensitizer is developed and the cytotoxic singlet oxygen generation capacity is analysed. Singlet oxygen quantum yields of active and inactive forms are determined to be 0.64 and 0.02, respectively. Selective photo-induced cell death in mouse melanoma cells over mammary and hepatocellular carcinoma proved the potential of the photosensitizer in tissue-selective therapies.

Graphical abstract: Enzyme activatable photodynamic therapy agents targeting melanoma

Supplementary files

Article information

Article type
Communication
Submitted
22 Oct 2022
Accepted
31 Oct 2022
First published
02 Nov 2022

Org. Biomol. Chem., 2022,20, 8864-8868

Enzyme activatable photodynamic therapy agents targeting melanoma

I. Verirsen, B. Uyar, N. G. Ozsamur, N. Demirok and S. Erbas-Cakmak, Org. Biomol. Chem., 2022, 20, 8864 DOI: 10.1039/D2OB01937J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements